Harnessing drug/radiation interaction through daily routine practice: Leverage medical and methodological point of view (MORSE 02-17 study)
Safety profile of the interaction between anticancer drugs and radiation is a recurrent question. However, there are little data regarding the non-anticancer treatment (NACT)/radiation combinations. The aim of the present study was to investigate concomitant NACTs in patients undergoing radiotherapy...
Saved in:
| Published in | Radiotherapy and oncology Vol. 129; no. 3; pp. 471 - 478 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Ireland
Elsevier B.V
01.12.2018
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0167-8140 1879-0887 1879-0887 |
| DOI | 10.1016/j.radonc.2018.06.010 |
Cover
| Abstract | Safety profile of the interaction between anticancer drugs and radiation is a recurrent question. However, there are little data regarding the non-anticancer treatment (NACT)/radiation combinations. The aim of the present study was to investigate concomitant NACTs in patients undergoing radiotherapy in a French comprehensive cancer center.
A prospective cross-sectional study was conducted. All cancer patients undergoing a palliative or curative radiotherapy were consecutively screened for six weeks in 2016. Data on NACTs were collected.
Out of 214 included patients, a NACT was concomitantly prescribed to 155 patients (72%), with a median number of 5 NACTs per patient (range: 1–12). The most prescribed drugs were anti-hypertensive drugs (101 patients, 47.2%), psychotropic drugs (n = 74, 34.6%), analgesics (n = 78, 36.4%), hypolipidemic drugs (n = 57, 26.6%), proton pump inhibitors (n = 46, 21.5%) and antiplatelet drugs (n = 38, 17.8%). Although 833 different molecules were reported, only 20 possible modifiers of cancer biological pathways (prescribed to 74 patients (34.5%)) were identified. Eight out of the 833 molecules (0.9%), belonging to six drug families, have been investigated in 28 ongoing or published clinical trials in combo with radiotherapy. They were prescribed to 63 patients (29.4%).
Drug-radiation interaction remains a subject of major interest, not only for conventional anticancer drugs, but also for NACTs. New trial designs are thus required. |
|---|---|
| AbstractList | Safety profile of the interaction between anticancer drugs and radiation is a recurrent question. However, there are little data regarding the non-anticancer treatment (NACT)/radiation combinations. The aim of the present study was to investigate concomitant NACTs in patients undergoing radiotherapy in a French comprehensive cancer center.
A prospective cross-sectional study was conducted. All cancer patients undergoing a palliative or curative radiotherapy were consecutively screened for six weeks in 2016. Data on NACTs were collected.
Out of 214 included patients, a NACT was concomitantly prescribed to 155 patients (72%), with a median number of 5 NACTs per patient (range: 1-12). The most prescribed drugs were anti-hypertensive drugs (101 patients, 47.2%), psychotropic drugs (n = 74, 34.6%), analgesics (n = 78, 36.4%), hypolipidemic drugs (n = 57, 26.6%), proton pump inhibitors (n = 46, 21.5%) and antiplatelet drugs (n = 38, 17.8%). Although 833 different molecules were reported, only 20 possible modifiers of cancer biological pathways (prescribed to 74 patients (34.5%)) were identified. Eight out of the 833 molecules (0.9%), belonging to six drug families, have been investigated in 28 ongoing or published clinical trials in combo with radiotherapy. They were prescribed to 63 patients (29.4%).
Drug-radiation interaction remains a subject of major interest, not only for conventional anticancer drugs, but also for NACTs. New trial designs are thus required. AbstractBackgroundSafety profile of the interaction between anticancer drugs and radiation is a recurrent question. However, there are little data regarding the non-anticancer treatment (NACT)/radiation combinations. The aim of the present study was to investigate concomitant NACTs in patients undergoing radiotherapy in a French comprehensive cancer center. MethodsA prospective cross-sectional study was conducted. All cancer patients undergoing a palliative or curative radiotherapy were consecutively screened for six weeks in 2016. Data on NACTs were collected. ResultsOut of 214 included patients, a NACT was concomitantly prescribed to 155 patients (72%), with a median number of 5 NACTs per patient (range: 1–12). The most prescribed drugs were anti-hypertensive drugs (101 patients, 47.2%), psychotropic drugs ( n = 74, 34.6%), analgesics ( n = 78, 36.4%), hypolipidemic drugs ( n = 57, 26.6%), proton pump inhibitors ( n = 46, 21.5%) and antiplatelet drugs ( n = 38, 17.8%). Although 833 different molecules were reported, only 20 possible modifiers of cancer biological pathways (prescribed to 74 patients (34.5%)) were identified. Eight out of the 833 molecules (0.9%), belonging to six drug families, have been investigated in 28 ongoing or published clinical trials in combo with radiotherapy . They were prescribed to 63 patients (29.4%). ConclusionDrug-radiation interaction remains a subject of major interest, not only for conventional anticancer drugs, but also for NACTs . New trial designs are thus required. Safety profile of the interaction between anticancer drugs and radiation is a recurrent question. However, there are little data regarding the non-anticancer treatment (NACT)/radiation combinations. The aim of the present study was to investigate concomitant NACTs in patients undergoing radiotherapy in a French comprehensive cancer center.BACKGROUNDSafety profile of the interaction between anticancer drugs and radiation is a recurrent question. However, there are little data regarding the non-anticancer treatment (NACT)/radiation combinations. The aim of the present study was to investigate concomitant NACTs in patients undergoing radiotherapy in a French comprehensive cancer center.A prospective cross-sectional study was conducted. All cancer patients undergoing a palliative or curative radiotherapy were consecutively screened for six weeks in 2016. Data on NACTs were collected.METHODSA prospective cross-sectional study was conducted. All cancer patients undergoing a palliative or curative radiotherapy were consecutively screened for six weeks in 2016. Data on NACTs were collected.Out of 214 included patients, a NACT was concomitantly prescribed to 155 patients (72%), with a median number of 5 NACTs per patient (range: 1-12). The most prescribed drugs were anti-hypertensive drugs (101 patients, 47.2%), psychotropic drugs (n = 74, 34.6%), analgesics (n = 78, 36.4%), hypolipidemic drugs (n = 57, 26.6%), proton pump inhibitors (n = 46, 21.5%) and antiplatelet drugs (n = 38, 17.8%). Although 833 different molecules were reported, only 20 possible modifiers of cancer biological pathways (prescribed to 74 patients (34.5%)) were identified. Eight out of the 833 molecules (0.9%), belonging to six drug families, have been investigated in 28 ongoing or published clinical trials in combo with radiotherapy. They were prescribed to 63 patients (29.4%).RESULTSOut of 214 included patients, a NACT was concomitantly prescribed to 155 patients (72%), with a median number of 5 NACTs per patient (range: 1-12). The most prescribed drugs were anti-hypertensive drugs (101 patients, 47.2%), psychotropic drugs (n = 74, 34.6%), analgesics (n = 78, 36.4%), hypolipidemic drugs (n = 57, 26.6%), proton pump inhibitors (n = 46, 21.5%) and antiplatelet drugs (n = 38, 17.8%). Although 833 different molecules were reported, only 20 possible modifiers of cancer biological pathways (prescribed to 74 patients (34.5%)) were identified. Eight out of the 833 molecules (0.9%), belonging to six drug families, have been investigated in 28 ongoing or published clinical trials in combo with radiotherapy. They were prescribed to 63 patients (29.4%).Drug-radiation interaction remains a subject of major interest, not only for conventional anticancer drugs, but also for NACTs. New trial designs are thus required.CONCLUSIONDrug-radiation interaction remains a subject of major interest, not only for conventional anticancer drugs, but also for NACTs. New trial designs are thus required. |
| Author | El Meddeb Hamrouni, A. He, M.Y. Magné, N. Vallard, A. Garcia, M.-A. Langrand-Escure, J. Vial, N. Ben Mrad, M. Trone, J.-C. Riocreux, C. Espenel, S. Ouni, S. Rehailia-Blanchard, A. Guillaume, E. Rancoule, C. Guy, J.-B. |
| Author_xml | – sequence: 1 givenname: A. surname: Vallard fullname: Vallard, A. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 2 givenname: C. surname: Rancoule fullname: Rancoule, C. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 3 givenname: S. surname: Espenel fullname: Espenel, S. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 4 givenname: M.-A. surname: Garcia fullname: Garcia, M.-A. organization: General Health Department, Hygée Institute, Avenue Albert Raimond, BP 60008, 42271 Saint-Priest en Jarez, France – sequence: 5 givenname: J. surname: Langrand-Escure fullname: Langrand-Escure, J. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 6 givenname: M.Y. surname: He fullname: He, M.Y. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 7 givenname: M. surname: Ben Mrad fullname: Ben Mrad, M. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 8 givenname: A. surname: El Meddeb Hamrouni fullname: El Meddeb Hamrouni, A. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 9 givenname: S. surname: Ouni fullname: Ouni, S. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 10 givenname: J.-C. surname: Trone fullname: Trone, J.-C. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 11 givenname: A. surname: Rehailia-Blanchard fullname: Rehailia-Blanchard, A. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 12 givenname: E. surname: Guillaume fullname: Guillaume, E. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 13 givenname: N. surname: Vial fullname: Vial, N. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 14 givenname: C. surname: Riocreux fullname: Riocreux, C. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 15 givenname: J.-B. surname: Guy fullname: Guy, J.-B. organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France – sequence: 16 givenname: N. surname: Magné fullname: Magné, N. email: nicolas.magne@icloire.fr organization: Radiotherapy Department, Lucien Neuwirth Cancer Institute, 42270 St Priest en Jarez, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29937210$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVkl9rUzEYxoNMXDf9BiK5nBfn7M35mwwRZGxOqAycXoc0edumniY1yZn0M_ill7bTC0GGV3lJfs8T8jw5IUfOOyTkNYOSAevOV2VQxjtdVsB4CV0JDJ6RCeO9KIDz_ohMMtYXnDVwTE5iXAFABXX_ghxXQtR9xWBCft2o4DBG6xbUhHFxnk2tStY7al3CoPR-Tsvgx8WSGmWHLc1zsg7pZn-s8YJO8T6zC6RrNFargSpn8pyW3vjBL_ZbG58dqZ_Te4s_6dnn2y93VxSqgvU0ptFs374kz-dqiPjqcT0l366vvl7eFNPbj58uP0wL3UKTikbVCrpZ3XJuOi5ms1ajwL5mfF41lRZcV4Zz3pnatE1OgAkBbYeCsx5607f1KTk7-G6C_zFiTHJto8ZhUA79GGUFrYBaNJxl9M0jOs7y0-Qm2LUKW_k7wAw0B0AHH2PA-R-Egdz1JFfy0JPc9SShk7CXXfwl0zbtY08hR_yU-P1BjDmkHGaQUVt0OkcfUCdpvP1fAz1YtyvpO24xrvwYXC5AMhkrCfJu949234jxGmoGTTZ492-Dp-9_APv-2UQ |
| CitedBy_id | crossref_primary_10_1016_j_radonc_2022_01_012 |
| Cites_doi | 10.1038/labinvest.2015.49 10.3892/or.2014.3068 10.1016/j.anl.2016.05.006 10.1046/j.1471-4159.2000.0721327.x 10.3892/ol.2014.2354 10.1038/srep00362 10.1530/ERC-14-0175 10.1093/jnci/95.9.646 10.1002/jcp.25092 10.1016/j.clon.2008.07.002 10.1152/ajpgi.00267.2010 10.1002/tox.22097 10.1016/j.ijrobp.2015.06.003 10.1016/j.canlet.2012.03.024 10.1073/pnas.1417636112 10.1016/j.ejca.2016.03.067 10.1016/j.radonc.2016.01.012 10.1016/j.bbrc.2013.10.112 10.1038/sj.onc.1203151 10.21873/anticanres.11469 10.1016/j.kjms.2016.07.008 10.1016/j.critrevonc.2008.09.016 10.1515/cmble-2015-0053 10.1016/j.canrad.2014.05.007 10.1667/RR13568.1 10.1186/1471-2407-14-498 10.1007/s12035-017-0423-8 10.18632/oncotarget.6304 10.1016/j.canep.2014.09.010 10.3109/10428194.2014.963575 10.18632/oncotarget.17387 10.3892/mmr.2017.6205 10.1038/sj.onc.1203183 10.18632/oncotarget.15356 10.1016/S1470-2045(08)70333-4 10.1016/j.tox.2016.09.018 10.1124/mol.114.096941 10.4161/cbt.10.1.11944 10.3349/ymj.2016.57.5.1124 10.1186/1476-4598-10-146 10.1002/med.20027 10.1016/j.ejca.2011.12.034 10.1186/1471-2407-14-96 10.1097/CAD.0000000000000349 10.18632/oncotarget.10078 10.1038/ncponc0744 10.1007/s10620-016-4225-z 10.1016/j.critrevonc.2017.01.014 |
| ContentType | Journal Article |
| Copyright | 2018 Elsevier B.V. Elsevier B.V. Copyright © 2018 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2018 Elsevier B.V. – notice: Elsevier B.V. – notice: Copyright © 2018 Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1016/j.radonc.2018.06.010 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-0887 |
| EndPage | 478 |
| ExternalDocumentID | 29937210 10_1016_j_radonc_2018_06_010 S0167814018303104 1_s2_0_S0167814018303104 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29P 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABMAC ABMZM ABOCM ABUDA ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 E3Z EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W J5H KOM M27 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SDF SDG SEL SES SEW SPCBC SSH SSU SSZ T5K UV1 WUQ X7M Z5R ZGI ZXP ~G- 0SF AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR NCXOZ AAYXX AGRNS CITATION NPM 7X8 |
| ID | FETCH-LOGICAL-c504t-4a3a06b3588d689bb5ce9e7318f242c98c2d8886d3d54167199056e981707d753 |
| IEDL.DBID | AIKHN |
| ISSN | 0167-8140 1879-0887 |
| IngestDate | Fri Sep 05 03:57:52 EDT 2025 Thu Apr 03 07:08:25 EDT 2025 Tue Jul 01 01:40:47 EDT 2025 Thu Apr 24 22:56:35 EDT 2025 Fri Feb 23 02:27:20 EST 2024 Sun Feb 23 10:18:57 EST 2025 Tue Aug 26 16:34:09 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Non-anti-cancer treatments Clinical trials Treatment interactions Radiation therapy Oncogenic pathways |
| Language | English |
| License | Copyright © 2018 Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c504t-4a3a06b3588d689bb5ce9e7318f242c98c2d8886d3d54167199056e981707d753 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 29937210 |
| PQID | 2059039481 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2059039481 pubmed_primary_29937210 crossref_primary_10_1016_j_radonc_2018_06_010 crossref_citationtrail_10_1016_j_radonc_2018_06_010 elsevier_sciencedirect_doi_10_1016_j_radonc_2018_06_010 elsevier_clinicalkeyesjournals_1_s2_0_S0167814018303104 elsevier_clinicalkey_doi_10_1016_j_radonc_2018_06_010 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-12-01 |
| PublicationDateYYYYMMDD | 2018-12-01 |
| PublicationDate_xml | – month: 12 year: 2018 text: 2018-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Ireland |
| PublicationPlace_xml | – name: Ireland |
| PublicationTitle | Radiotherapy and oncology |
| PublicationTitleAlternate | Radiother Oncol |
| PublicationYear | 2018 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Palumbo, Matrone, Montesi, Bellavita, Lupattelli, Saldi (b0165) 2017; 37 Yoshiji, Kuriyama, Kawata, Yoshii, Ikenaka, Noguchi (b0245) 2001; 7 Wei, Xu, Liu, Li, Zhou (b0230) 2017; 8 Rentala, Chintala, Guda, Chintala, Komarraju, Mangamoori (b0190) 2013; 441 Tsai, Tsai, Chiu, Lu, Kuo, Chang (b0215) 2016; 31 Chin, Li, Lee, Huang, Wang, Lai (b0025) 2016; 231 Piazuelo, Esquivias, De Martino, Cebrián, Conde, Santander (b0180) 2016; 61 Pang, Wang, Chen, Wu, Shao, Xiao (b0170) 2015; 56 Cinatl, Kotchetkov, Blaheta, Driever, Vogel, Cinatl (b0030) 2002; 20 Guo, Wang, Wang, Qiao, Tang (b0075) 2017; 8 Koh, Kim, Kim, Kim, Jung, Song (b0100) 2011; 301 Eikawa, Nishida, Mizukami, Yamazaki, Nakayama, Udono (b0045) 2015; 112 Mu, Xu, Yang, Huang, Xiao, Li (b0150) 2014; 31 Jang, Hong, Kim, Kim, Jang, Park (b0085) 2016; 7 Oliveira, Dal-Cim, Lopes, Ludka, Nedel, Tasca (b0160) 2018; 55 Gaist, Hallas, Friis, Hansen, Sørensen (b0060) 2014; 38 Chen, Huang, Jiang, Manji (b0020) 1999; 72 Chargari, Toillon, Macdermed, Castadot, Magné (b0015) 2009; 10 James, Sydes, Clarke, Mason, Dearnaley, Anderson (b0080) 2008; 20 Koritzinsky (b0105) 2015; 93 Song, Lee, Dings, Williams, Powers, Santos (b0200) 2012; 2 Xia, Tong, Zhou, Duan, Xu, Zeng (b0240) 2016; 20 Fendrich, Lopez, Manoharan, Maschuw, Wichmann, Baier (b0055) 2014; 21 Song, Wei, Lu, Huang, Li, Chen (b0205) 2017; 15 Gu, Zhang, Zhou, Ma, Yao, Ji (b0070) 2014; 8 Zhang, Ma, Hu, Zhang (b0260) 2010; 10 Rouhani, Goliaei, Khodagholi, Nikoofar (b0195) 2014; 17 Colevas, Brown, Hahn, Mitchell, Camphausen, Coleman (b0035) 2003; 95 Blaheta, Michaelis, Driever, Cinatl (b0010) 2005; 25 Li, Zhang, Zhang, Yang, Shao, Luo (b0120) 2014; 14 Lu, Lin, LaPushin, Cuevas, Fang, Yu (b0125) 1999; 18 Groll, Petrikat, Vetter, Wenz, Dengjel, Gretzmeier (b0065) 2016; 370 Magné, Chargari, Soria, Deutsch (b0130) 2009; 70 Langrand-Escure, Vallard, Rivoirard, Méry, Guy, Espenel (b0110) 2016; 27 Numico, Fusco, Franco, Roila (b0155) 2017; 111 Yu, Guo, Chen, Guo, Du, Li (b0250) 2016; 32 Paramio, Navarro, Segrelles, Gómez-Casero, Jorcano (b0175) 1999; 18 Fasih, Elbaz, Hüttemann, Konski, Zielske (b0050) 2014; 182 Thariat, Kirova, Milano, Mornex (b0210) 2014; 18 Kim, Kang, Kim, Han, Kim (b0095) 2015; 20 Maity, De, Das, Banerjee, Sarkar, Banerjee (b0135) 2015; 95 Pulkoski-Gross, Li, Zheng, Li, Ouyang, Rigas (b0185) 2015; 87 Wang, Seah, Loh, Chan, Hartman, Goh (b0220) 2016; 7 Eguchi, Suzuki, Ida, Kudo, Ando, Ebara (b0040) 2017; 44 Bentzen, Harari, Bernier (b0005) 2007; 4 Moncharmont, Levy, Gilormini, Bertrand, Chargari, Alphonse (b0140) 2012; 322 Moon, Lee, Lee, Chung, Park, Park (b0145) 2016; 57 Wink, Belderbos, Dieleman, Rossi, Rasch, Damhuis (b0235) 2016; 118 Jin, Lee, Pfent, Safe (b0090) 2014; 14 Zhang, Ma, Wang, Zhang, Guo, Wang (b0255) 2011; 10 Levy, Chargari, Marabelle, Perfettini, Magné, Deutsch (b0115) 2016; 62 Wedlake, Silia, Benton, Lalji, Thomas, Dearnaley (b0225) 2012; 48 Jin (10.1016/j.radonc.2018.06.010_b0090) 2014; 14 Chin (10.1016/j.radonc.2018.06.010_b0025) 2016; 231 Blaheta (10.1016/j.radonc.2018.06.010_b0010) 2005; 25 Bentzen (10.1016/j.radonc.2018.06.010_b0005) 2007; 4 Cinatl (10.1016/j.radonc.2018.06.010_b0030) 2002; 20 Yu (10.1016/j.radonc.2018.06.010_b0250) 2016; 32 Li (10.1016/j.radonc.2018.06.010_b0120) 2014; 14 Wedlake (10.1016/j.radonc.2018.06.010_b0225) 2012; 48 Guo (10.1016/j.radonc.2018.06.010_b0075) 2017; 8 Jang (10.1016/j.radonc.2018.06.010_b0085) 2016; 7 Wang (10.1016/j.radonc.2018.06.010_b0220) 2016; 7 Chargari (10.1016/j.radonc.2018.06.010_b0015) 2009; 10 Langrand-Escure (10.1016/j.radonc.2018.06.010_b0110) 2016; 27 Piazuelo (10.1016/j.radonc.2018.06.010_b0180) 2016; 61 Magné (10.1016/j.radonc.2018.06.010_b0130) 2009; 70 Tsai (10.1016/j.radonc.2018.06.010_b0215) 2016; 31 Levy (10.1016/j.radonc.2018.06.010_b0115) 2016; 62 Song (10.1016/j.radonc.2018.06.010_b0200) 2012; 2 Pang (10.1016/j.radonc.2018.06.010_b0170) 2015; 56 Eguchi (10.1016/j.radonc.2018.06.010_b0040) 2017; 44 Kim (10.1016/j.radonc.2018.06.010_b0095) 2015; 20 Lu (10.1016/j.radonc.2018.06.010_b0125) 1999; 18 Thariat (10.1016/j.radonc.2018.06.010_b0210) 2014; 18 Numico (10.1016/j.radonc.2018.06.010_b0155) 2017; 111 Zhang (10.1016/j.radonc.2018.06.010_b0255) 2011; 10 James (10.1016/j.radonc.2018.06.010_b0080) 2008; 20 Yoshiji (10.1016/j.radonc.2018.06.010_b0245) 2001; 7 Wei (10.1016/j.radonc.2018.06.010_b0230) 2017; 8 Fasih (10.1016/j.radonc.2018.06.010_b0050) 2014; 182 Koritzinsky (10.1016/j.radonc.2018.06.010_b0105) 2015; 93 Rentala (10.1016/j.radonc.2018.06.010_b0190) 2013; 441 Fendrich (10.1016/j.radonc.2018.06.010_b0055) 2014; 21 Groll (10.1016/j.radonc.2018.06.010_b0065) 2016; 370 Maity (10.1016/j.radonc.2018.06.010_b0135) 2015; 95 Wink (10.1016/j.radonc.2018.06.010_b0235) 2016; 118 Song (10.1016/j.radonc.2018.06.010_b0205) 2017; 15 Palumbo (10.1016/j.radonc.2018.06.010_b0165) 2017; 37 Oliveira (10.1016/j.radonc.2018.06.010_b0160) 2018; 55 Colevas (10.1016/j.radonc.2018.06.010_b0035) 2003; 95 Chen (10.1016/j.radonc.2018.06.010_b0020) 1999; 72 Gu (10.1016/j.radonc.2018.06.010_b0070) 2014; 8 Koh (10.1016/j.radonc.2018.06.010_b0100) 2011; 301 Moncharmont (10.1016/j.radonc.2018.06.010_b0140) 2012; 322 Moon (10.1016/j.radonc.2018.06.010_b0145) 2016; 57 Rouhani (10.1016/j.radonc.2018.06.010_b0195) 2014; 17 Eikawa (10.1016/j.radonc.2018.06.010_b0045) 2015; 112 Gaist (10.1016/j.radonc.2018.06.010_b0060) 2014; 38 Paramio (10.1016/j.radonc.2018.06.010_b0175) 1999; 18 Zhang (10.1016/j.radonc.2018.06.010_b0260) 2010; 10 Xia (10.1016/j.radonc.2018.06.010_b0240) 2016; 20 Mu (10.1016/j.radonc.2018.06.010_b0150) 2014; 31 Pulkoski-Gross (10.1016/j.radonc.2018.06.010_b0185) 2015; 87 |
| References_xml | – volume: 70 start-page: 206 year: 2009 end-page: 215 ident: b0130 article-title: Concomitant chemo-radiotherapy in clinical trials: to promote step by step rational development publication-title: Crit Rev Oncol Hematol – volume: 14 start-page: 498 year: 2014 ident: b0090 article-title: The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis publication-title: BMC Cancer – volume: 31 start-page: 866 year: 2016 end-page: 876 ident: b0215 article-title: AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF-κB pathway publication-title: Environ Toxicol – volume: 182 start-page: 50 year: 2014 end-page: 59 ident: b0050 article-title: Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway publication-title: Radiat Res – volume: 20 start-page: 937 year: 2015 end-page: 947 ident: b0095 article-title: Ramipril inhibits high glucose-stimulated up-regulation of adhesion molecules via the ERK1/2 MAPK signaling pathway in human umbilical vein endothelial cells publication-title: Cell Mol Biol Lett – volume: 15 start-page: 1909 year: 2017 end-page: 1915 ident: b0205 article-title: Metformin suppresses the expression of Sonic hedgehog in gastric cancer cells publication-title: Mol Med Rep – volume: 10 start-page: 19 year: 2010 end-page: 29 ident: b0260 article-title: β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NF-κB and AP-1 publication-title: Cancer Biol Therapy – volume: 20 start-page: 97 year: 2002 end-page: 106 ident: b0030 article-title: Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha publication-title: Int J Oncol – volume: 18 start-page: 7034 year: 1999 end-page: 7045 ident: b0125 article-title: The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells publication-title: Oncogene – volume: 25 start-page: 383 year: 2005 end-page: 397 ident: b0010 article-title: Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies publication-title: Med Res Rev – volume: 17 start-page: 352 year: 2014 end-page: 360 ident: b0195 article-title: Lithium increases radiosensitivity by abrogating DNA repair in breast cancer spheroid culture publication-title: Arch Iran Med – volume: 27 start-page: 427 year: 2016 end-page: 432 ident: b0110 article-title: Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report publication-title: Anticancer Drugs – volume: 2 start-page: 362 year: 2012 ident: b0200 article-title: Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells publication-title: Sci Rep – volume: 32 start-page: 439 year: 2016 end-page: 445 ident: b0250 article-title: Captopril pretreatment protects the lung against severe acute pancreatitis induced injury via inhibiting angiotensin II production and suppressing Rho/ROCK pathway publication-title: Kaohsiung J Med Sci – volume: 8 start-page: 20842 year: 2017 end-page: 20850 ident: b0230 article-title: Effect of captopril on radiation-induced TGF-β1 secretion in EA.Hy926 human umbilical vein endothelial cells publication-title: Oncotarget – volume: 18 start-page: 7462 year: 1999 end-page: 7468 ident: b0175 article-title: PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein publication-title: Oncogene – volume: 322 start-page: 139 year: 2012 end-page: 147 ident: b0140 article-title: Targeting a cornerstone of radiation resistance: cancer stem cell publication-title: Cancer Lett – volume: 20 start-page: 577 year: 2008 end-page: 581 ident: b0080 article-title: STAMPEDE: systemic therapy for advancing or metastatic prostate cancer–a multi-arm multi-stage randomised controlled trial publication-title: Clin Oncol (R Coll Radiol) – volume: 7 start-page: 1073 year: 2001 end-page: 1078 ident: b0245 article-title: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor publication-title: Clin Cancer Res – volume: 31 start-page: 2107 year: 2014 end-page: 2114 ident: b0150 article-title: Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer publication-title: Oncol Rep – volume: 44 start-page: 122 year: 2017 end-page: 125 ident: b0040 article-title: Successful treatment of radiation-induced mucositis with proton pump inhibitor administration: a report of two laryngeal cancer cases publication-title: Auris Nasus Larynx – volume: 20 start-page: 157 year: 2016 end-page: 165 ident: b0240 article-title: Tramadol inhibits proliferation, migration and invasion via α2-adrenoceptor signaling in breast cancer cells publication-title: Eur Rev Med Pharmacol Sci – volume: 8 start-page: 1739 year: 2014 end-page: 1744 ident: b0070 article-title: Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines publication-title: Oncol Lett – volume: 111 start-page: 144 year: 2017 end-page: 151 ident: b0155 article-title: Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use publication-title: Crit Rev Oncol Hematol – volume: 95 start-page: 646 year: 2003 end-page: 651 ident: b0035 article-title: Radiation Modifier Working Group of the National Cancer Institute. Development of investigational radiation modifiers publication-title: J Natl Cancer Inst – volume: 55 start-page: 1509 year: 2018 end-page: 1523 ident: b0160 article-title: Atorvastatin promotes cytotoxicity and reduces migration and proliferation of human A172 glioma cells publication-title: Mol Neurobiol – volume: 56 start-page: 1821 year: 2015 end-page: 1830 ident: b0170 article-title: Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1α and c-MYC publication-title: Leuk Lymphoma – volume: 37 start-page: 1453 year: 2017 end-page: 1457 ident: b0165 article-title: Statins protect against acute RT-related rectal toxicity in patients with prostate cancer: an observational prospective study publication-title: Anticancer Res – volume: 95 start-page: 702 year: 2015 end-page: 717 ident: b0135 article-title: Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition publication-title: Lab Invest – volume: 48 start-page: 2117 year: 2012 end-page: 2124 ident: b0225 article-title: Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies publication-title: Eur J Cancer – volume: 61 start-page: 2896 year: 2016 end-page: 2907 ident: b0180 article-title: Acetylsalicylic acid exhibits antitumor effects in esophageal adenocarcinoma cells in vitro and in vivo publication-title: Dig Dis Sci – volume: 10 start-page: 53 year: 2009 end-page: 60 ident: b0015 article-title: Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale? publication-title: Lancet Oncol – volume: 57 start-page: 1124 year: 2016 end-page: 1130 ident: b0145 article-title: Concomitant statin use has a favorable effect on Gemcitabine-Erlotinib combination chemotherapy for advanced pancreatic cancer publication-title: Yonsei Med J – volume: 38 start-page: 722 year: 2014 end-page: 727 ident: b0060 article-title: Statin use and survival following glioblastoma multiforme publication-title: Cancer Epidemiol – volume: 62 start-page: 36 year: 2016 end-page: 45 ident: b0115 article-title: Can immunostimulatory agents enhance the abscopal effect of radiotherapy? publication-title: Eur J Cancer – volume: 7 start-page: 46219 year: 2016 end-page: 46229 ident: b0085 article-title: Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer publication-title: Oncotarget – volume: 14 start-page: 96 year: 2014 ident: b0120 article-title: Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway publication-title: BMC Cancer – volume: 87 start-page: 501 year: 2015 end-page: 512 ident: b0185 article-title: Repurposing the antipsychotic trifluoperazine as an antimetastasis agent publication-title: Mol Pharmacol – volume: 7 start-page: 2532 year: 2016 end-page: 2544 ident: b0220 article-title: Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway publication-title: Oncotarget – volume: 231 start-page: 459 year: 2016 end-page: 472 ident: b0025 article-title: Selective β2-AR blockage suppresses colorectal cancer growth through regulation of EGFR-Akt/ERK1/2 signaling, G1-phase arrest, and apoptosis publication-title: J Cell Physiol – volume: 72 start-page: 1327 year: 1999 end-page: 1330 ident: b0020 article-title: The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3 publication-title: J Neurochem – volume: 93 start-page: 454 year: 2015 end-page: 464 ident: b0105 article-title: Metformin: a novel biological modifier of tumor response to radiation therapy publication-title: Int J Radiat Oncol Biol Phys – volume: 112 start-page: 1809 year: 2015 end-page: 1814 ident: b0045 article-title: Immune-mediated antitumor effect by type 2 diabetes drug, metformin publication-title: Proc Natl Acad Sci USA – volume: 370 start-page: 94 year: 2016 end-page: 105 ident: b0065 article-title: Inhibition of β-catenin signaling by phenobarbital in hepatoma cells in vitro publication-title: Toxicology – volume: 10 start-page: 146 year: 2011 ident: b0255 article-title: β2-adrenoceptor blockage induces G1/S phase arrest and apoptosis in pancreatic cancer cells via Ras/Akt/NFκB pathway publication-title: Mol Cancer – volume: 118 start-page: 453 year: 2016 end-page: 459 ident: b0235 article-title: Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy publication-title: Radiother Oncol – volume: 8 start-page: 39640 year: 2017 end-page: 39648 ident: b0075 article-title: Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response publication-title: Oncotarget – volume: 21 start-page: 813 year: 2014 end-page: 824 ident: b0055 article-title: Enalapril and ASS inhibit tumor growth in a transgenic mouse model of islet cell tumors publication-title: Endocr Relat Cancer – volume: 4 start-page: 172 year: 2007 end-page: 180 ident: b0005 article-title: Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions publication-title: Nat Clin Pract Oncol – volume: 441 start-page: 586 year: 2013 end-page: 592 ident: b0190 article-title: Atorvastatin inhibited Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK) mediated adhesion and differentiation of CD133 + CD44+ prostate cancer stem cells publication-title: Biochem Biophys Res Commun – volume: 18 start-page: 270 year: 2014 end-page: 279 ident: b0210 article-title: Combination of stereotactic irradiation and chemotherapy or targeted therapies: state of the art and preliminary recommendations publication-title: Cancer Radiother – volume: 301 start-page: G9 year: 2011 end-page: 19 ident: b0100 article-title: Fluoxetine inhibits NF-κB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice publication-title: Am J Physiol Gastrointest Liver Physiol – volume: 20 start-page: 157 year: 2016 ident: 10.1016/j.radonc.2018.06.010_b0240 article-title: Tramadol inhibits proliferation, migration and invasion via α2-adrenoceptor signaling in breast cancer cells publication-title: Eur Rev Med Pharmacol Sci – volume: 95 start-page: 702 year: 2015 ident: 10.1016/j.radonc.2018.06.010_b0135 article-title: Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition publication-title: Lab Invest doi: 10.1038/labinvest.2015.49 – volume: 31 start-page: 2107 year: 2014 ident: 10.1016/j.radonc.2018.06.010_b0150 article-title: Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer publication-title: Oncol Rep doi: 10.3892/or.2014.3068 – volume: 44 start-page: 122 year: 2017 ident: 10.1016/j.radonc.2018.06.010_b0040 article-title: Successful treatment of radiation-induced mucositis with proton pump inhibitor administration: a report of two laryngeal cancer cases publication-title: Auris Nasus Larynx doi: 10.1016/j.anl.2016.05.006 – volume: 72 start-page: 1327 year: 1999 ident: 10.1016/j.radonc.2018.06.010_b0020 article-title: The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3 publication-title: J Neurochem doi: 10.1046/j.1471-4159.2000.0721327.x – volume: 7 start-page: 1073 year: 2001 ident: 10.1016/j.radonc.2018.06.010_b0245 article-title: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor publication-title: Clin Cancer Res – volume: 8 start-page: 1739 year: 2014 ident: 10.1016/j.radonc.2018.06.010_b0070 article-title: Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines publication-title: Oncol Lett doi: 10.3892/ol.2014.2354 – volume: 2 start-page: 362 year: 2012 ident: 10.1016/j.radonc.2018.06.010_b0200 article-title: Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells publication-title: Sci Rep doi: 10.1038/srep00362 – volume: 21 start-page: 813 year: 2014 ident: 10.1016/j.radonc.2018.06.010_b0055 article-title: Enalapril and ASS inhibit tumor growth in a transgenic mouse model of islet cell tumors publication-title: Endocr Relat Cancer doi: 10.1530/ERC-14-0175 – volume: 95 start-page: 646 year: 2003 ident: 10.1016/j.radonc.2018.06.010_b0035 article-title: Radiation Modifier Working Group of the National Cancer Institute. Development of investigational radiation modifiers publication-title: J Natl Cancer Inst doi: 10.1093/jnci/95.9.646 – volume: 231 start-page: 459 year: 2016 ident: 10.1016/j.radonc.2018.06.010_b0025 article-title: Selective β2-AR blockage suppresses colorectal cancer growth through regulation of EGFR-Akt/ERK1/2 signaling, G1-phase arrest, and apoptosis publication-title: J Cell Physiol doi: 10.1002/jcp.25092 – volume: 20 start-page: 577 year: 2008 ident: 10.1016/j.radonc.2018.06.010_b0080 article-title: STAMPEDE: systemic therapy for advancing or metastatic prostate cancer–a multi-arm multi-stage randomised controlled trial publication-title: Clin Oncol (R Coll Radiol) doi: 10.1016/j.clon.2008.07.002 – volume: 301 start-page: G9 year: 2011 ident: 10.1016/j.radonc.2018.06.010_b0100 article-title: Fluoxetine inhibits NF-κB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice publication-title: Am J Physiol Gastrointest Liver Physiol doi: 10.1152/ajpgi.00267.2010 – volume: 17 start-page: 352 year: 2014 ident: 10.1016/j.radonc.2018.06.010_b0195 article-title: Lithium increases radiosensitivity by abrogating DNA repair in breast cancer spheroid culture publication-title: Arch Iran Med – volume: 31 start-page: 866 year: 2016 ident: 10.1016/j.radonc.2018.06.010_b0215 article-title: AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF-κB pathway publication-title: Environ Toxicol doi: 10.1002/tox.22097 – volume: 93 start-page: 454 year: 2015 ident: 10.1016/j.radonc.2018.06.010_b0105 article-title: Metformin: a novel biological modifier of tumor response to radiation therapy publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2015.06.003 – volume: 322 start-page: 139 year: 2012 ident: 10.1016/j.radonc.2018.06.010_b0140 article-title: Targeting a cornerstone of radiation resistance: cancer stem cell publication-title: Cancer Lett doi: 10.1016/j.canlet.2012.03.024 – volume: 112 start-page: 1809 year: 2015 ident: 10.1016/j.radonc.2018.06.010_b0045 article-title: Immune-mediated antitumor effect by type 2 diabetes drug, metformin publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1417636112 – volume: 62 start-page: 36 year: 2016 ident: 10.1016/j.radonc.2018.06.010_b0115 article-title: Can immunostimulatory agents enhance the abscopal effect of radiotherapy? publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.03.067 – volume: 118 start-page: 453 year: 2016 ident: 10.1016/j.radonc.2018.06.010_b0235 article-title: Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy publication-title: Radiother Oncol doi: 10.1016/j.radonc.2016.01.012 – volume: 20 start-page: 97 year: 2002 ident: 10.1016/j.radonc.2018.06.010_b0030 article-title: Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha publication-title: Int J Oncol – volume: 441 start-page: 586 year: 2013 ident: 10.1016/j.radonc.2018.06.010_b0190 article-title: Atorvastatin inhibited Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK) mediated adhesion and differentiation of CD133 + CD44+ prostate cancer stem cells publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2013.10.112 – volume: 18 start-page: 7462 year: 1999 ident: 10.1016/j.radonc.2018.06.010_b0175 article-title: PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein publication-title: Oncogene doi: 10.1038/sj.onc.1203151 – volume: 37 start-page: 1453 year: 2017 ident: 10.1016/j.radonc.2018.06.010_b0165 article-title: Statins protect against acute RT-related rectal toxicity in patients with prostate cancer: an observational prospective study publication-title: Anticancer Res doi: 10.21873/anticanres.11469 – volume: 32 start-page: 439 year: 2016 ident: 10.1016/j.radonc.2018.06.010_b0250 article-title: Captopril pretreatment protects the lung against severe acute pancreatitis induced injury via inhibiting angiotensin II production and suppressing Rho/ROCK pathway publication-title: Kaohsiung J Med Sci doi: 10.1016/j.kjms.2016.07.008 – volume: 70 start-page: 206 year: 2009 ident: 10.1016/j.radonc.2018.06.010_b0130 article-title: Concomitant chemo-radiotherapy in clinical trials: to promote step by step rational development publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2008.09.016 – volume: 20 start-page: 937 year: 2015 ident: 10.1016/j.radonc.2018.06.010_b0095 article-title: Ramipril inhibits high glucose-stimulated up-regulation of adhesion molecules via the ERK1/2 MAPK signaling pathway in human umbilical vein endothelial cells publication-title: Cell Mol Biol Lett doi: 10.1515/cmble-2015-0053 – volume: 18 start-page: 270 year: 2014 ident: 10.1016/j.radonc.2018.06.010_b0210 article-title: Combination of stereotactic irradiation and chemotherapy or targeted therapies: state of the art and preliminary recommendations publication-title: Cancer Radiother doi: 10.1016/j.canrad.2014.05.007 – volume: 182 start-page: 50 year: 2014 ident: 10.1016/j.radonc.2018.06.010_b0050 article-title: Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway publication-title: Radiat Res doi: 10.1667/RR13568.1 – volume: 14 start-page: 498 year: 2014 ident: 10.1016/j.radonc.2018.06.010_b0090 article-title: The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis publication-title: BMC Cancer doi: 10.1186/1471-2407-14-498 – volume: 55 start-page: 1509 year: 2018 ident: 10.1016/j.radonc.2018.06.010_b0160 article-title: Atorvastatin promotes cytotoxicity and reduces migration and proliferation of human A172 glioma cells publication-title: Mol Neurobiol doi: 10.1007/s12035-017-0423-8 – volume: 7 start-page: 2532 year: 2016 ident: 10.1016/j.radonc.2018.06.010_b0220 article-title: Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway publication-title: Oncotarget doi: 10.18632/oncotarget.6304 – volume: 38 start-page: 722 year: 2014 ident: 10.1016/j.radonc.2018.06.010_b0060 article-title: Statin use and survival following glioblastoma multiforme publication-title: Cancer Epidemiol doi: 10.1016/j.canep.2014.09.010 – volume: 56 start-page: 1821 year: 2015 ident: 10.1016/j.radonc.2018.06.010_b0170 article-title: Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1α and c-MYC publication-title: Leuk Lymphoma doi: 10.3109/10428194.2014.963575 – volume: 8 start-page: 39640 year: 2017 ident: 10.1016/j.radonc.2018.06.010_b0075 article-title: Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response publication-title: Oncotarget doi: 10.18632/oncotarget.17387 – volume: 15 start-page: 1909 year: 2017 ident: 10.1016/j.radonc.2018.06.010_b0205 article-title: Metformin suppresses the expression of Sonic hedgehog in gastric cancer cells publication-title: Mol Med Rep doi: 10.3892/mmr.2017.6205 – volume: 18 start-page: 7034 year: 1999 ident: 10.1016/j.radonc.2018.06.010_b0125 article-title: The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells publication-title: Oncogene doi: 10.1038/sj.onc.1203183 – volume: 8 start-page: 20842 year: 2017 ident: 10.1016/j.radonc.2018.06.010_b0230 article-title: Effect of captopril on radiation-induced TGF-β1 secretion in EA.Hy926 human umbilical vein endothelial cells publication-title: Oncotarget doi: 10.18632/oncotarget.15356 – volume: 10 start-page: 53 year: 2009 ident: 10.1016/j.radonc.2018.06.010_b0015 article-title: Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale? publication-title: Lancet Oncol doi: 10.1016/S1470-2045(08)70333-4 – volume: 370 start-page: 94 year: 2016 ident: 10.1016/j.radonc.2018.06.010_b0065 article-title: Inhibition of β-catenin signaling by phenobarbital in hepatoma cells in vitro publication-title: Toxicology doi: 10.1016/j.tox.2016.09.018 – volume: 87 start-page: 501 year: 2015 ident: 10.1016/j.radonc.2018.06.010_b0185 article-title: Repurposing the antipsychotic trifluoperazine as an antimetastasis agent publication-title: Mol Pharmacol doi: 10.1124/mol.114.096941 – volume: 10 start-page: 19 year: 2010 ident: 10.1016/j.radonc.2018.06.010_b0260 article-title: β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NF-κB and AP-1 publication-title: Cancer Biol Therapy doi: 10.4161/cbt.10.1.11944 – volume: 57 start-page: 1124 year: 2016 ident: 10.1016/j.radonc.2018.06.010_b0145 article-title: Concomitant statin use has a favorable effect on Gemcitabine-Erlotinib combination chemotherapy for advanced pancreatic cancer publication-title: Yonsei Med J doi: 10.3349/ymj.2016.57.5.1124 – volume: 10 start-page: 146 year: 2011 ident: 10.1016/j.radonc.2018.06.010_b0255 article-title: β2-adrenoceptor blockage induces G1/S phase arrest and apoptosis in pancreatic cancer cells via Ras/Akt/NFκB pathway publication-title: Mol Cancer doi: 10.1186/1476-4598-10-146 – volume: 25 start-page: 383 year: 2005 ident: 10.1016/j.radonc.2018.06.010_b0010 article-title: Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies publication-title: Med Res Rev doi: 10.1002/med.20027 – volume: 48 start-page: 2117 year: 2012 ident: 10.1016/j.radonc.2018.06.010_b0225 article-title: Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies publication-title: Eur J Cancer doi: 10.1016/j.ejca.2011.12.034 – volume: 14 start-page: 96 year: 2014 ident: 10.1016/j.radonc.2018.06.010_b0120 article-title: Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway publication-title: BMC Cancer doi: 10.1186/1471-2407-14-96 – volume: 27 start-page: 427 year: 2016 ident: 10.1016/j.radonc.2018.06.010_b0110 article-title: Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report publication-title: Anticancer Drugs doi: 10.1097/CAD.0000000000000349 – volume: 7 start-page: 46219 year: 2016 ident: 10.1016/j.radonc.2018.06.010_b0085 article-title: Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer publication-title: Oncotarget doi: 10.18632/oncotarget.10078 – volume: 4 start-page: 172 year: 2007 ident: 10.1016/j.radonc.2018.06.010_b0005 article-title: Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions publication-title: Nat Clin Pract Oncol doi: 10.1038/ncponc0744 – volume: 61 start-page: 2896 year: 2016 ident: 10.1016/j.radonc.2018.06.010_b0180 article-title: Acetylsalicylic acid exhibits antitumor effects in esophageal adenocarcinoma cells in vitro and in vivo publication-title: Dig Dis Sci doi: 10.1007/s10620-016-4225-z – volume: 111 start-page: 144 year: 2017 ident: 10.1016/j.radonc.2018.06.010_b0155 article-title: Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2017.01.014 |
| SSID | ssj0002037 |
| Score | 2.2592833 |
| Snippet | Safety profile of the interaction between anticancer drugs and radiation is a recurrent question. However, there are little data regarding the non-anticancer... AbstractBackgroundSafety profile of the interaction between anticancer drugs and radiation is a recurrent question. However, there are little data regarding... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 471 |
| SubjectTerms | Clinical trials Hematology, Oncology, and Palliative Medicine Non-anti-cancer treatments Oncogenic pathways Radiation therapy Treatment interactions |
| Title | Harnessing drug/radiation interaction through daily routine practice: Leverage medical and methodological point of view (MORSE 02-17 study) |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0167814018303104 https://www.clinicalkey.es/playcontent/1-s2.0-S0167814018303104 https://dx.doi.org/10.1016/j.radonc.2018.06.010 https://www.ncbi.nlm.nih.gov/pubmed/29937210 https://www.proquest.com/docview/2059039481 |
| Volume | 129 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBbJBkovpelz-wgq9NAe3LWth-3cQkjYPjaFpoHchCzJYUtqL97dQy_9A_3TmbGkJaUpKb3ZRmPZ0uibEZr5hpDXdQZOtXUiaWrGEg4OQVKbyiWSFUwKI005hPzPTuT0jH84F-db5DDmwmBYZcB-j-kDWocnkzCak8V8PjnFAHrkawKlRH5Lvk12clZJMSI7B-8_Tk82gJynnjoTKb5RIGbQDWFevbZdi1yGmSfyxFTamy3U3zzQwRId3yf3ggtJD_xX7pIt1z4gd2bhkPwh-TXVPQIYGCVq-_XFpEf-AZwAiuQQvU9loKFCD7V6fvmDwvUKpGnMmtqnnxxoOaAN_e7PcqhuLfUFpyNg0kUHb6RdQ_GAgb6Zff5yekSxjklBB97at4_I2fHR18NpEmouJEakfJVwzXQqaybK0sqyqmthXOUKWPkNGHNTlSa3sGmWllkBvlyRgTUT0lXI81dY2Ps8JqO2a91TQrm1jXScQWPBubHaAJpYUzcOdkFloceExXFWJhCSY12MSxUjz74pPzsKZ0dhAF6WjkmykVp4Qo5b2os4hSommwI8KrAYt8gVN8m5ZVjjS5WpZa5S9YceXpf8TZX_oc9XUccUrHI8utGt69ZLaCSqlCGzzpg88cq3-fscXUzYuT_7736fk7t456N0XpDRql-7l-Brreo9sv3uZ7YXVtQVUYsnYA |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKkaAXxJvlOUgc4BA2WT-ScENVqwV2i0RbqTfLsR20qE1W2d0DF_4Af5qZ2Ckgioq4RYknTuzxzFj-5hvGXlQZBtXOy6SuOE8EBgRJZUufKJ5zJa2yRQ_5nx-o6bF4fyJPttjukAtDsMpo-4NN7611vDOOozleLhbjQwLQE18TKiXxW4or7KqQPCdc3-tvP3EekzQQZxLBNzUf8ud6kFdnXNsQk2EWaDwpkfZi__S3-LP3Q_s32Y0YQMLb8I232JZvbrNr83hEfod9n5qOzBe6JHDd5vO4I_YBGn4gaoguJDJArM8DzixOvwJer1EahpypNzDzqONoa-AsnOSAaRyEctODuYRli2-EtgY6XoCX84-fDveAqpjk0LPWvrrLjvf3jnanSay4kFiZinUiDDepqrgsCqeKsqqk9aXPcd3X6MptWdiJwy2zctxJjOTyDH2ZVL4klr_c4c7nHttu2sY_YCCcq5UXHBtLIawzFm2Js1XtcQ9U5GbE-DDO2kY6cqqKcaoH3NkXHWZH0-xogt9l6Ygl51LLQMdxSXs5TKEeUk3ROGr0F5fI5RfJ-VVc4Sud6dVEp_oPLfxV8jdF_oc-nw86pnGN08GNaXy7WWEjWaaceHVG7H5QvvO_n1CAifv2h__d7zN2fXo0n-nZu4MPj9gOPQl4ncdse91t_BOMutbV035V_QDWUigr |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Harnessing+drug%2Fradiation+interaction+through+daily+routine+practice%3A+Leverage+medical+and+methodological+point+of+view+%28MORSE+02-17+study%29&rft.jtitle=Radiotherapy+and+oncology&rft.au=Vallard%2C+A&rft.au=Rancoule%2C+C&rft.au=Espenel%2C+S&rft.au=Garcia%2C+M-A&rft.date=2018-12-01&rft.eissn=1879-0887&rft.volume=129&rft.issue=3&rft.spage=471&rft_id=info:doi/10.1016%2Fj.radonc.2018.06.010&rft_id=info%3Apmid%2F29937210&rft.externalDocID=29937210 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01678140%2FS0167814018X00152%2Fcov150h.gif |